Abstract:Tumor angiogenesis is dependent on growth factors, and inhibition of their pathways is one of the promising strategies in cancer therapy. However, resistance to single pathway has been a great concern in clinical trials so that it necessitates multiple targetable factors for developing tumor angiogenesis inhibitors. Moreover, the strategy of Fc fusion protein is an attractive platform for novel peptide agents, which gains increasing importance with FDA approval because of better immunogenicity and stability. Here, we applied the Fc fusion protein concept to bFGF/VEGFA pathways and designed a multi-epitope Peptibody with immunogenic peptides derived from human bFGF and VEGFA sequences. Immunization with Peptibody could elicit high-titer anti-bFGF and anti-VEGFA antibodies, activate T cells, and induce Th1/Th2-type cytokines. In in vitro experiments, the isolated anti-Peptibody antibody inhibited the proliferation and migration of A549 cells and human umbilical vein endothelial cells (HUVECs) by decreasing the MAPK/Akt/mTOR signal pathways. In the murine tumor model, pre-immunization with Peptibody suppressed the tumor growth and neovascularization of lung cancer by decreasing the production of bFGF/VEGFA/PDGF, the MAPK/Akt/mTOR signal pathways, and the activation of suppressive cells in tumor sites. Further, the biological characterizations of the recombinant Peptibody were investigated systematically, including protein primary structure, secondary structure, stability, and toxicity. Collectively, the results highlighted the strategy of bFGF/VEGFA pathways and Fc fusion protein in suppressing tumor progression and angiogenesis, which emphasized the potential of multiple targetable factors for producing enduring clinical responses in tumor patients.

Identification of a novel peptide that blocks basic fibroblast growth factor-mediated cell proliferation.

Isolation of a novel basic FGF-binding peptide with potent antiangiogenetic activity.

Identification of a Novel Afgf-Binding Peptide with Anti-Tumor Effect on Breast Cancer from Phage Display Library

A Novel Bfgf Antagonist Peptide Inhibits Breast Cancer Cell Growth.

Expression and Purification of FGFR1-Fc Fusion Protein and Its Effects on Human Lung Squamous Carcinoma

A novel FGF2 antagonist peptide P8 with potent antiproliferation activity

Suppression of Tumor Growth and Metastasis by a VEGFR-1 Antagonizing Peptide Identified from a Phage Display Library.

Anti-Proliferation Effect of a Short Peptide on Bfgf-Induced Human Gastric Cancer Cells

Screening a novel FGF3 antagonist peptide with anti-tumor effects on breast cancer from a phage display library

Effects of a Synthetic Bfgf Antagonist Peptide on the Proteome of 3T3 Cells Stimulated with Bfgf

A bFGF Antagonist Peptide with Anti-angiogenesis Properties in Non-small Cell Lung Cancer Cells

Inhibition of Proliferation of Non-small Cell Lung Cancer Cells by a Bfgf Antagonist Peptide

Screening a Phage Display Library for a Novel FGF8b-binding Peptide with Anti-Tumor Effect on Prostate Cancer

An FGF8b-mimicking Peptide with Potent Antiangiogenic Activity.

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 Using a Phage Display Peptide Library

A Novel Fgfr1-Binding Peptide Exhibits Anti-Tumor Effect On Lung Cancer By Inhibiting Proliferation And Angiogenesis

Selection of Peptide Ligands Binding to Fibroblast Growth Factor from A Phage Peptide Library

Activity Study of Specific Bfgf-Binding Phage

The Design, Characterizations, and Tumor Angiogenesis Inhibition of a Multi-Epitope Peptibody with Bfgf/vegfa

A Short Peptide Derived from the Gn Helix Domain of Fgf8b Suppresses the Growth of Human Prostate Cancer Cells

A Cyclic Peptide Epitope of an Under-Explored VEGF-B Loop 1 Demonstrated In Vivo Anti-Angiogenic and Anti-Tumor Activities